SCHEMBL2833245

SCHEMBL2833245

NC1(OC(=O)O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2827340 0.95 TSHR (0.32)
SCHEMBL2831752 0.92 TSHR (0.36)
SCHEMBL1840485 0.92 TSHR (0.36)
SCHEMBL2832088 0.92 TSHR (0.36)
SCHEMBL873141 0.89
Hydrochloric Acid SCHEMBL11029381 0.86
SCHEMBL19392125 0.79
SCHEMBL3164465 0.79 TSHR (0.37)
SCHEMBL14059088 0.79 TSHR (0.32)
SCHEMBL4624265 0.78 KDM4E (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3250191-B1 TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING NOVO NORDISK AS (DK) 2024-01-17 EP claimed
EP-2637698-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2022-04-20 EP claimed
EP-2932981-B1 Albumin-binding derivatives of GLP-1 NOVO NORDISK AS (DK) 2021-06-16 EP claimed
EP-3225631-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2019-01-09 EP claimed
EP-2190872-B1 GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE NOVO NORDISK AS (DK) 2018-03-14 EP claimed
EP-3010546-B1 GLP-1 DERIVATIVES AND USES THEREOF NOVO NORDISK AS (DK) 2017-08-09 EP claimed
EP-2846824-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2017-04-05 EP claimed
EP-2753642-B1 GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2017-03-01 EP claimed
EP-2696687-B1 DOUBLE-ACYLATED GLP-1 DERIVATIVES NOVO NORDISK AS (DK) 2016-10-26 EP claimed
EP-2190873-B1 TRUNCATED GLP-1 DERIVATIVES AND THEIR THERAPEUTICAL USE NOVO NORDISK AS (DK) 2015-07-22 EP claimed
EP-2398483-B1 OXYNTOMODULIN ANALOGS MERCK SHARP & DOHME (US) 2014-09-24 EP claimed
EP-1863521-B1 EXTENDED GLP-1 COMPOUNDS NOVO NORDISK AS (DK) 2014-05-07 EP claimed
EP-2045265-B1 GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance BIOCOMPATIBLES UK LTD (GB) 2012-11-21 EP claimed
EP-1926748-B1 GLP-1 ( GLUCAGON-LIKE PEPTIDE-1 ) FUSION POLYPEPTIDES WITH INCREASED PEPTIDASE RESISTANCE BIOCOMPATIBLES UK LTD (GB) 2012-08-29 EP claimed
EP-1863839-B1 ACYLATED GLP-1 COMPOUNDS NOVO NORDISK AS (DK) 2010-08-04 EP claimed
EP-1704165-B1 GLP-1 COMPOUNDS NOVO NORDISK AS (DK) 2010-03-17 EP claimed
EP-1767545-B1 GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance BIOCOMPATIBLES UK LTD (GB) 2009-11-11 EP claimed
EP-0552417-B1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-07-07 EP claimed
EP-0528312-B1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-07-16 EP claimed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP claimed